- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07410117
REGN7508 til voksne deltagere til forebyggelse af kræftrelateret trombose (ROXI-CAT-I)
En fase 3, multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse for at vurdere effektiviteten og sikkerheden af REGN7508, en monoklonal antistof mod FXI, til primær profylakse af kræftrelateret trombose hos deltagere med solide tumorer under kræftbehandling (ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-mail: clinicaltrials@regeneron.com
Studiesteder
-
-
Florida
-
Hialeah, Florida, Forenede Stater, 33013
- Rekruttering
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach, Florida, Forenede Stater, 33169
- Rekruttering
- Helios Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso, Texas, Forenede Stater, 79902
- Trukket tilbage
- El Paso Medical Research Institute (Medresearch Inc)
-
-
-
-
-
Tbilisi, Georgien, 0159
- Rekruttering
- Institute of Clinical Oncology
-
Tbilisi, Georgien, 0186
- Rekruttering
- Caucasus Medical Centre
-
Tbilisi, Georgien, 0144
- Rekruttering
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi, Georgien, 0179
- Rekruttering
- LTD Cancer Research Centre
-
Tbilisi, Georgien, 0179
- Rekruttering
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi, Georgien, 0102
- Rekruttering
- American Hospital Tbilisi
-
Tbilisi, Georgien, 0112
- Rekruttering
- Llc Todua Clinic
-
Tbilisi, Georgien, 0112
- Rekruttering
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi, Adjara, Georgien, 6000
- Rekruttering
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi, Imereti, Georgien, 4600
- Rekruttering
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata, Japan, 951-8520
- Rekruttering
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Rekruttering
- Ehime University Hospital
-
-
Gunma
-
Ōta, Gunma, Japan, 373-8550
- Rekruttering
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi, Hyōgo, Japan, 673-8558
- Rekruttering
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun, Kagawa-ken, Japan, 761-0793
- Rekruttering
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi, Kanagawa, Japan, 259-1193
- Rekruttering
- Tokai University Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 602-8566
- Rekruttering
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Rekruttering
- Tohoku University Hospital
-
-
Osaka
-
Chuo, Osaka, Japan, 540-0006
- Rekruttering
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi, Saitama, Japan, 362-0806
- Rekruttering
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku, Tokyo, Japan, 104-0045
- Rekruttering
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku, Tokyo, Japan, 160-0023
- Rekruttering
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Rekruttering
- Yamaguchi University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Administered per the protocol |
|
Eksperimentel: REGN7508
|
Administered per the protocol
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tid til første hændelse af centralt bedømt International Society of Thrombosis and Hemostasis (ISTH) større blødning eller klinisk relevant ikke-større (CRNM) blødning
Tidsramme: I 6 måneder
|
I 6 måneder
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Tidsramme: Through 6 months
|
Through 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Forekomst af behandlingsrelaterede bivirkninger (TEAEs)
Tidsramme: Op til dag 245
|
Op til dag 245
|
|
Sværhedsgrad af TEAE'er
Tidsramme: Op til dag 245
|
Op til dag 245
|
|
Størrelsen af ADA til REGN7508
Tidsramme: Op til dag 245
|
Op til dag 245
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Tidsramme: Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Tidsramme: Up to day 245
|
Up to day 245
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- R7508-CAT-2392
- 2024-519298-21-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-delingsadgangskriterier
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .